Health
Exploring Ongoing Trials With 177Lu-PSMA-617 in Prostate Cancer – Targeted Oncology
Arun Azad, MBBS, PhD, discusses ongoing studies of lutetium-177-PSMA radionuclide in patients with prostate cancer.
Arun Azad, MBBS, PhD, an associate professor at Peter MacCallum Cancer Centre and the University of Melbourne, and chair of the ANZUP Cancer Trials Group Translational, discusses ongoing studies of lutetium-177-PSMA (177Lu-PSMA-617) radionuclide in patients with prostate cancer.
Theres the UpFrontPSMA trial (NCT04343885), a randomized phase 2 study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel alone in patients with metastatic hormone-naïve prostate cancer that is recruiting right now….
-
Business20 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News19 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General14 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News16 hours agoTips to improve engagement – Proctor